Synthesis of Cyclopentapyridine and Thienopyridine Derivatives as Potential Calcium Channel Modulators

M. G. Gündüz; C. Şafak; B. Kaygısız; B. Ç. Koşar; R. Şimşek; K. Erol; A. Linden

doi:10.1055/s-0031-1299744

Arzneimittelforschung, Inhaltsverzeichnis

Arzneimittelforschung 2012; 62(04): 167-175
DOI: 10.1055/s-0031-1299744

Original Article

Synthesis of Cyclopentapyridine and Thienopyridine Derivatives as Potential Calcium Channel Modulators

M. G. Gündüz

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

,

C. Şafak

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

,

B. Kaygısız

²Department of Pharmacology, Faculty of Medicine, Osman Gazi University, Eskişehir, Turkey

,

B. Ç. Koşar

²Department of Pharmacology, Faculty of Medicine, Osman Gazi University, Eskişehir, Turkey

,

R. Şimşek

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

,

K. Erol

²Department of Pharmacology, Faculty of Medicine, Osman Gazi University, Eskişehir, Turkey

,

A. Linden

³Institute of Organic Chemistry, University of Zurich Zurich, Switzerland

› Institutsangaben

Abstract

In this study, novel condensed 1,4-dihydropyridines bearing cyclopentanone (1–21) or tetrahydrothiophene-1,1-dioxide ring (22–42) with various ester substituents were synthesized via a modified Hantzsch reaction and their calcium channel modulator activities were investigated on isolated rat ileum and rat thoracic aorta. The introduction of a cyclopentanone ring fused to the 1,4-dihydropyridine nucleus and methyl, ethyl and allyl moieties to the ester group led to more active calcium modulators.

Key words

1,4-Dihydropyridine - thienopyridine - cyclopentapyridine - calcium channel modulator

Volltext

Referenzen

References
1 Triggle DJ, Swamy VC. Pharmacology of agents that affect calcium: Agonists and antagonists. Chest 1980; 78: 174-179
2 Zamponi GW. Antagonist binding sites of voltage dependent calcium channels. Drug Dev Res 1997; 42: 131-143
3 Dolphin AC. A short history of voltage-gated calcium channels. Br J Pharmacol 2006; 147: S56-S62
4 Vaghy PL, Williams JS, Schwartz A. 1987; Receptor pharmacology of calcium entry blocking agents. Am J Cardiol 1987;59 9A-17A
5 Triggle DJ. The 1,4-dihydropyridine nucleus: a pharmacophoric template part 1. Actions at ion channels. Mini Rev Med Chem 2003; 3 (03) 215-223
6 Şafak C, Şimşek R. Fused 1,4-dihydropyridines as potential calcium modulatory compounds. Mini Rev Med Chem 2006; 6 (07) 747-755
7 Gordeev MF, Patel DV, England BP et al. Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorgan Med Chem 1998; 6 (07) 883-889
8 Şimşek R, Öztürk GS, Vural İM et al. Synthesis and calcium modulatory activity of 3-alkyloxy-carbonyl-4-(disubstituted)aryl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives. Arch Pharm Chem Life Sci 2008; 341 (01) 55-60
9 Rose U. 5-Oxo-1,4-dihydroindenopyridines: Calcium modulators with partial calcium agonistic activity. J Heterocycl Chem 1990; 27 (02) 237-242
10 Tu S, Miao C, Fang F et al. New potential calcium channel modulators: design and synthesis of compounds containing two pyridine, pyrimidine, pyridone, quinoline and acridine units under microwave irradiation. Bioorg Med Chem Lett 2004; 14 (06) 1533-1536
11 Şimşek R, Şafak C, Erol K et al. Synthesis, evaluation of the calcium antagonistic activity and biotransformation of hexahydroquinoline and furoquinoline derivatives. Arzneim Forsch 2003; 53 (03) 159-166
12 Miri R, Javidnia K, Sarkarzadeh H et al. Synthesis, pharmacological activity and study of 3D structures of some lipophilic 1,4-dihydropyridines as calcium channel antagonists. Bioorg Med Chem 2006; 14: 4842-4849
13 Goldmann S, Stoltefuss J. 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew Chem Int Edit 1991; 30 (12) 1559-1578
14 Mohajeri A, Hemmateenejad B, Mehdipour A et al. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLA. J Mol Graphics Model 2008; 26: 1057-1065
15 Coburn RA, Wierzba M, Suto MJ et al. 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J Med Chem 1988; 31 (11) 2103-2107
16 Yagupolskii LM, Maletina IA, Petko KI et al. New fluorine-containing hypotensive preparations. J Fluorine Chem 2001; 109 (01) 87-94
17 Dodd JH, Schwender CF, Moore Jr JB et al. Design and discovery of RWJ 22108 – a novel bronchoselective calcium channel blocker. Drug Des Discov 1998; 15 (03) 135-148
18 Altenbach RJ, Kalvoda L, Carroll WA. A convenient multigram scale synthesis of tetrahydrothiophene-3-one-1,1-dioxide. Synth Commun 2004; 34 (04) 567-570
19 Kazda S, Garthoff B, Meyer H et al. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate (nisoldipine, Bay K 5552). Arzneim Forsch 1980; 30 (12) 2144-2162
20 Rose U, Dräger M. Synthesis, configuration and calcium modulatory properties of enantiomerically pure 5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylates. J Med Chem 1992; 35: 2238-2243
21 Linden A, Şafak C, Şimşek R et al. Two 1,4-dihydropyridine derivatives with potential calcium-channel antagonist activity. Acta Crystallogr C 2011; 67: o80-o84